Loading ...
| Programs + Specialties |
|
| Training + Education |
Hahnemann Medical College of Philadelphia; Boston University Medical Center; Emory University Medical Center; Grady Memorial Hospital
|
| Board Certifications |
Internal Medicine, Nephrology |
| NPI # |
1265541155 |
| Gender |
Male |
| Accepted Insurances |
View Accepted Insurances at Tufts Medical Center
|
Tufts Medical Center
4th Floor
35 Kneeland St.
Box 391
Boston, MA 02111
Phone #: 617-636-5866
Fax #: 617-636-2369
|
2021, "Top Doctor", Boston Magazine
2020, "Top Doctor," Boston Magazine
2018/2019, "Top Doctor," Boston Magazine
2019, Nephrology Honoree at the National Kidney Foundation Honors Event
2017, "Top Doctor," Boston Magazine
2017, Lillian Jean Kaplan International Prize, International Society of Nephrology
2016 – 2019, America’s Top Doctors (digital guide)
2014, Physician of the Year from the Polycystic Kidney Disease Foundation
2014, Donald W. Seldin Distinguished Award from the National Kidney Foundation
2009-2015, "Top Doctor," Boston Magazine
2012, "Top Doctor" and in top 1% in the nation in his specialty, U.S. News & World Report
2009, Distinguished Faculty Award from Tufts University School of Medicine
2007, Gift of Life Award - Outstanding Physician in Nephrology, National Kidney Foundation of MA, RI, NH and VT
2002, Citation for Excellence in Teaching by the Class of 2002 Tufts University School of Medicine
2001-2015, America’s Top Doctors (book series): Editions 1 – 14
2001-2002 Tufts University School of Medicine Excellence in Teaching Award from the Third Year Medical Students
2000-2001, Tufts University School of Medicine Excellence in Teaching Award from the Third Year Medical Students
View a full list of Dr. Perrone's publications
here.
Dr. Perrone is the Director of the Polycystic Kidney Disease Center at Tufts Medical Center. His present work focuses on clinical research in polycystic kidney disease and the role of total kidney volume as a biomarker in response to clinical therapies. Dr. Perrone was a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation from 1999 to 2016 (Chairman from 2006-2010) and frequently lectures at national and local patient meetings.
Dr. Perrone has had a major role in global and national clinical trials for ADPKD. He served as site PI and member of the steering committee for the TEMPO 251 and REPRISE studies of tolvaptan in ADPKD. Dr. Perrone was site PI and member of the steering committee for the NIDDK-sponsored HALT PKD study. Dr. Perrone and colleagues at the University of Maryland, Baltimore, and the University of Pittsburgh received a 5-year grant from the Department of Defense to study metformin as a clinical intervention in ADPKD (TAME PKD). This trial has completed its recruitment goals and will report results in 2021. Dr. Perrone is co-Principal Investigator and co-chair of the steering committee for the Sanofi PKD trial of venglustat (STAGED-PKD), site PI of the Kadmon PKD trial of tesevatinib, and site PI of the Reata PKD trial of bardoxolone (Falcon).
Over the past 10 years, Dr. Perrone has been integral to the formation of the PKD Outcomes Consortium and has been the principal individual involved in bringing together the contributors from academia, pharma, NIH, FDA, CDISC, and C-Path. He has led this large and diverse consortium that is creating the groundwork for validation of total kidney volume as a clinical trial and regulatory endpoint in ADPKD. Dr. Perrone’s goal, enhanced by prior experience in epithelial biology, clinical trials, dietary modification, and translation of basic discoveries to clinical care, is to improve outcomes in chronic kidney disease, particularly polycystic kidney disease.
Dr. Perrone is the Scientific Director of the Clinical and Translational Research Center (CTRC), under the auspices of the Tufts Clinical and Translational Science Institute. The CTRC is the main site for clinical research studies at Tufts Medical Center. His role is to provide scientific leadership and facilitate research activities in the CTRC.
Member, American Society of Nephrology
Member, International Society of Nephrology
Fellow, National Kidney Foundation
Fellow, American Society of Nephrology
Clinical
Dr. Perrone’s patient care interests are in polycystic kidney disease, general nephrology, acid-base disorders, hypertension, and kidney transplantation medicine. He is the Director of the Polycystic Kidney Disease Center.
Research
Dr. Perrone’s research interests are largely focused in the area of polycystic kidney disease, including slowing progression and determining the natural history of the extrarenal complications. In prior studies, he addressed the mortality of extrarenal complications of polycystic kidney disease after kidney failure treated by dialysis. He will continue this work in collaboration with Drs. Alan Collins and Blanche Chavers of the United States Renal Data System.
Dr. Perrone also is the Principal Investigator of the Boston Patient Care Center of an NIH-funded multi-center clinical trial (HALT Progression in PKD, part of the Polycystic Kidney Disease Clinical Trials Network). This study uses angiotensin converting enzyme inhibitors in combination with angiotensin receptor blockers to slow the progression of polycystic kidney disease and utilizes the unique endpoint of kidney volume growth as assessed using magnetic resonance imaging. Tufts Medical Center is one of the four national HALT-PKD Study centers that will conduct this 6-year, $25 million study sponsored by the NIH. Drs. Perrone (the PI) and Miskulin direct the study that started in the winter of 2006.
Dr. Perrone is the Tufts Medical Center Principal Investigator of the TEMPO 3/4 study. TEMPO 3/4 is a global trial that is addressing the efficacy of the vasopressin-receptor antagonist tolvaptan to slow progression of polycystic kidney disease. The unique endpoint of kidney volume growth will be assessed using magnetic resonance imaging. Tufts Medical Center is one of 100 international TEMPO 3/4 Study centers.
4//2016, “Update on the Management of ADPKD in 2016 and Beyond”, Spring Clinical Meetings, National Kidney Foundation, Boston, MA
5/19/2016, “Management of Hypertension in ADPKD”, Symposium on Hypertension, Klinik Hirslanden, Zurich, Switzerland
6/2/2016, “Predicting Disease Progression and Management of ADPKD”, Keynote address at the Jared J. Grantham Symposium, Kansas University PKD Center, Kansas City, KS
6/26/2016, “Emerging Therapies in PKD”, PKD Foundation National Convention, Orlando, FL
6/26/2016, “Clinical Trials: Why YOU Should Participate”, PKD Foundation National Convention, Orlando, FL
6/26/2016, “Native Nephrectomy and Kidney Transplantation: If? When? How?”, Panelist, PKD Foundation National Convention, Orlando, FL
10/20/16, “Using CDISC Standards to Map Clinical Information in ADPKD”, Embedding Clinical Standards in Research: Development, Implementation, and Curation. By webex, sponsored by European Bioinformatics Institute, Cambridge, UK
11/17/2016, “Incorporating Patient Perspectives to Develop Patient-Centric Therapies”, American Society of Nephrology Annual Meeting, Chicago, IL.
4/23/17, “Total Kidney Volume: A Biomarker for PKD Progression,” World Congress of Nephrology, Mexico City, Mexico
6/8/17, “Total Kidney Volume: Where have we been and where are we going?,” Grantham Symposium, PKD EAB Meeting, Kansas City, MO.
6/29/17, “Lessons from CRISP, HALD PKD, TEMPO and the PKD Outcomes Consortium: TKV and other Biomarkers,” Polycystic Kidney Disease: Challenges, Differing Viewpoints and Ways Forward, sponsored by the Federation of American Societies for Experimental Biology, Big Sky, MT
9/15/2017, “Management of ADPKD in 2017”, as part of An Update on Recent Advances and Clinical Management in 2017 Toronto PKD Scientific Day, Toronto, Canada
11/4/17, “Treatment of ADPKD: Where Are We Now?” Continuing Medical Education Symposium: ADPKD – Advances in Pathogenesis and Treatment, American Society of Nephrology Annual Meeting, New Orleans, LA
11/13/17, “REPRISE (Tolvaptan) Clinical Trial Results,” Live National Webinar on behalf of the PKD Foundation.
12/2/17, “Lessons from CRISP, HALT PKD, TEMPO and the PKD Outcomes Consortium: TKV and other Biomarkers,” at Management of Polycystic Kidney Diseases from Childhood to Adulthood, University Leuven, Leuven, Belgium
7/12/2018, “FDA Biomarker Qualification and MRI Imaging Parameters qualified by FDA (PKDOC Measures)”. Renal Imaging Workshop, NIDDK, Bethesda MD
9/14/2018, “Management of ADPKD in 2018”, 2018 Toronto PKD Scientific Conference, Toronto, Canada
10/24/2018, “Emerging therapies and promising clinical trials” in early course: PKD: Translating Mechanisms into Therapy at 2018 ASN Kidney Week, San Diego, CA.
11/18/2018, “Long-term treatment of PQRAD (ADPKD) with Tolvaptan”, XLVIII Congress of the Spanish Society of Nephrology and IX Iberoamerican Congress of Nephrology, Madrid, Spain
12/6/2018, “Advances in the Management of ADPKD”, Charité – Universitätsmedizin, Berlin, Germany
12/7/2018, “Optimal management of ADPKD in patients prior to dialysis”, 31st Berliner DialyseSeminar, Berlin, Germany
